Thiazolyl-dihydro-chinazoline

Abstract

Disclosed are compounds of general formula (I), wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

1 . A compound of the formula (I),  
     
       
         
         
             
             
         
       
     
     wherein 
 A denotes N or CH;  
 R a  denotes hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl and C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -alkyl,  
 R b  denotes hydrogen, OH or NH 2  
 or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl, CONH 2 , C 6 -C 14 -aryl-NH, C 3 -C 8 -heterocycloalkyl-NH— and O—C 1 -C 3 -alkyl,  
 
 R 1  denotes hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl and C 6 -C 14 -aryl-C 1 -C 5 -alkyl-; 
 or  
 
 R 2  denotes hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 6 -alkyl, C 9 -C 13 -spiro, C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 6 -alkyl- and C 6 -C 14 -aryl-C 1 -C 6 -alkyl-;  
 or  
 R 1  and R 2  together form an optionally substituted five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen. 
 or  
 
 R 1  and R 2  together form an optionally substituted nine- to thirteen-membered spirocyclic ring, 
 or  
 
 R 2  denotes a group selected from among general formulae (A1) to (A18)  
                                       
 wherein  
 X and Y may be linked to the same or different atoms of G, and  
 X denotes a bond or an optionally substituted group selected from among C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, 
 or  
 
 X together with R 1 , R 3  or R 4  may form a C 1 -C 7 -alkylene bridge;  
 Y denotes a bond or optionally substituted C 1 -C 4 -alkylene;  
 Q denotes an optionally substituted group selected from among C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, or  
 Q together with R 1 , R 3  or R 4  may form a C 1 -C 7 -alkylene bridge;  
 R 3 , R 4 , R 5  which may be identical or different, denote hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, NR 7 R 8 , NR 7 R 8 —C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 6 -C 14 -aryl and C 5 -C 10 -heteroaryl; 
 or in each case two of the substituents  
 
 R 3 , R 4 , R 5  together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;  
 G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;  
 R 6  which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C 1 -C 8 -alkyl, C 2 -C 6 -alkenyl C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 5 -C 10 -heteroaryl and C 3 -C 8 -heterocycloalkyl, 
 or  
 a group selected from among NR 7 R 8 , OR 7 , —CO—C 1 -C 3 -alkyl-NR 7 R 8 —O—C 1 -C 3 -alkyl-NR 7 R 8 , CONR 7 R 8 , NR 7 COR 8 , —CO—C 1 -C 3 -alkyl-NR 7 (CO)OR 8 , —O(CO)NR 7 R 8 , NR 7 (CO)NR 8 R 9 , NR 7 (CO)OR 8 , (CO)OR 7 , —O(CO)R 7 , COR 7 , (SO)R 7 , (SO 2 )R 7 , (SO 2 )NR 7 R 8 , NR 7 (SO 2 )R 8 , NR 7 (SO 2 )NR 8 R 9 , CN, —C 1 -C 3 -alkyl-C 6 -C 14 -aryl, —NH—CO—NH—C 1 -C 3 -alkyl and halogen;  
 
 n denotes 1, 2 or 3  
 R 7 , R 8 , R 9  which may be identical or different, denote hydrogen or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 3 -alkyl, C 6 -C 14 -aryl, C 1 -C 4 -alkyl-C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 4 -alkyl, C 3 -C 8 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 4 -alkyl (CO)— and C 1 -C 4 -alkyl-O(CO)—; 
 or in each case two of the substituents  
 
 R 7 , R 8 , R 9  together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; 
 optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, as well as optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof,  
 with the proviso that the following compounds are excluded:  
 
 a) 8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 b) 1-methyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 c) 1,1-dimethyl-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 d) 1-(2-dimethylamino-ethyl)-3-(8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 e) 4-methyl-piperazine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide  
 f) piperidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide  
 g) pyrrolidine-1-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide  
 h) 1-methyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 i) (8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea  
 j) 1,1-dimethyl-3-(8-o-tolyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-urea and  
 k) [8-(2-methoxy-phenyl)-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl]-urea and 
 l) morpholine-4-carboxylic acid (8-phenyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-amide  
 
 
   
   
       2 . The compound according to  claim 1 , 
 wherein    X, Y, Q and G may have the meaning specified and    A denotes N,    R a  denotes hydrogen or a group selected from among C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl and C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among 
 C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 2 -C 6 -alkynyl-NR 5 R 6 , C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, C 1 -C 4 -alkoxy, CN, NO 2 , NR 10 R 11 , OR 10 , COR 10 , COOR 10 , CONR 10 R 11 , NR 10 COR 11 , NR 10 (CO)NR 11 R 12 , O(CO)NR 10 R 11 , NR 10 (CO)OR 11 , SO 2 R 10 , SOR 10 , SO 2 NR 10 R 11 , NR 10 SO 2 NR 11 R 12  and NR 10 SO 2 R 11 ;  
 or R a  is optionally substituted by a group of general formula (B)  
                     
 wherein,  
 R 13  to R 16  which may be identical or different, represent hydrogen or C 1 -C 6 -alkyl,  
 or two of the substituents  
 R 13  to R 16  together form an optionally substituted five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;  
   R 10 , R 11 , R 12  which may be identical or different, denote hydrogen or a group selected from among 
 C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl and C 1 -C 6  haloalkyl;  
 or  
 in each case two of the groups  
   R 10 , R 11 , R 12  together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen;    R b  denotes hydrogen, OH or NH 2  
 or an optionally substituted group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 4 -alkyl, spiro, C 3 -C 8 -heterocycloalkyl, CONH 2 , C 6 -C 14 -aryl-NH, C 3 -C 8 -heterocycloalkyl-NH— and O—C 1 -C 3 -alkyl,  
 which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among  
 C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, OMe, CN, NH 2 , NHMe and NMe 2 ;  
   R 1  denotes hydrogen or a group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl and C 6 -C 14 -aryl-C 1 -C 5 -alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, COOH, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)-alkyl and —(CO)O-alkyl,    R 2  denotes hydrogen or a group selected from among C 1 -C 8  alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 8 -alkenyl, C 3 -C 8 -cycloalkenyl, C 1 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 5 -alkyl, C 5 -C 10 -heteroaryl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 8 -cycloalkenyl-C 1 -C 4 -alkyl, C 5 -C 10 -heteroaryl-C 1 -C 6 -alkyl, C 9 -C 13 -spiro, C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 6 -alkyl- and C 6 -C 14 -aryl-C 1 -C 6 -alkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)-alkyl, ═O, COOH and —(CO)O-alkyl. 
 or  
   R 1  and R 2  together form a five-, six- or seven-membered ring consisting of carbon atoms and optionally 1 to 2 heteroatoms, selected from among oxygen, sulphur and nitrogen, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, C 1 -C 6 -alkyl, OMe, —NH(CO)—C 1 -C 4 -alkyl, and —(CO)O—C 1 -C 4 -alkyl. 
 or  
   R 1  and R 2  together form an optionally substituted nine- to thirteen-membered spirocyclic ring, 
 or  
   R 2  denotes a group selected from among general formulae (A1) to (A18)                                            wherein    R 3 , R 4 , R 5  which may be identical or different, denote hydrogen or a group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl, NR 7 R 8 , NR 7 R 8 —C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 6 -C 14 -aryl and C 5 -C 10 -heteroaryl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, NR 9 R 10 , —NH(CO)—C 1 -C 4 -alkyl and MeO, 
 or in each case two of the substituents  
   R 3 , R 4 , R 5  together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, NR 9 R 10 , —NH(CO)—C 1 -C 4 -alkyl and MeO,    R 6  which may be identical or different, denote hydrogen or a group, selected from among C 1 -C 8 -alkyl, C 2 -C 6 -alkenyl C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 6 -C 14 -aryl, C 5 -C 10 -heteroaryl and C 3 -C 8 -heterocycloalkyl, which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among NH 2 , NHMe, NMe 2 , OH, OMe, CN, —C 1 -C 3 -alkyl-C 6 -C 14 -aryl, —NH—CO—NH—C 1 -C 3 -alkyl, C 1 -C 6 -alkyl and —(CO)O—C 1 -C 6 -alkyl 
 or  
 a group selected from among ═O, NR 7 R 8 , OR 7 , —CO—C 1 -C 3 -alkyl-NR 7 R 8 —R—C 1 -C 3 -alkyl-NR 7 R 8 , CONR 7 R 8 , NR 7 COR 8 , —CO—C 1 -C 3 -alkyl-NR 7 (CO)OR 8 , —O(CO)NR 7 R 8 , NR 7 (CO)NR 8 R 9 , NR 7 (CO)OR 8 , (CO)OR 7 , —O(CO)R 7 , COR 7 , (SO)R 7 , (SO 2 )R 7 , (SO 2 )NR 7 R 8 , NR 7 (SO 2 )R 8 , NR 7 (SO 2 )NR 8 R 9 , CN and halogen;  
   n denotes 1, 2 or 3    R 7 , R 8 , R 9  which may be identical or different, denote hydrogen or a group selected from among C 1 -C 8 -alkyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -haloalkyl, C 1 -C 4 -alkyl-C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 3 -alkyl, C 6 -C 14 -aryl, C 1 -C 4 -alkyl-C 6 -C 14 -aryl, C 6 -C 14 -aryl-C 1 -C 4 -alkyl, C 3 -C 8 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl, C 3 -C 8 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 4 -alkyl (CO)— and C 1 -C 4 -alkyl-O(CO), which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, OMe, NHMe, NMe 2 , C 1 -C 6 -alkyl and (CO)O C 1 -C 6 -alkyl, 
 or in each case two of the substituents  
   R 7 , R 8 , R 9  together form a five-, six- or seven-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen, sulphur and nitrogen; which may optionally be substituted by one or more of the groups, which may be identical or different, selected from among halogen, NH 2 , OH, CN, OMe, NH Me, NMe 2 , C 1 -C 6 -alkyl and (CO)OC 1 -C 6 -alkyl.    
   
   
       3 . The compound according to  claim 2 , 
 wherein    A, R a  and R 1  to R 16  may have the meaning specified and    R b  denotes hydrogen.    
   
   
       4 . The compound according to  claim 2 , 
 wherein    A, R 1  to R 16  may have the meaning specified,    R a  denotes C 6 -C 14 -aryl or C 1 -C 6 -alkyl 
 wherein R a  may optionally be substituted by one or more of the groups, which may be identical or different, selected from among C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 1 -C 6 -haloalkyl, halogen, OH, C 1 -C 4 -alkoxy, CN, NO 2 , NR 10 R 11 , OR 10 , COR 10 , COOR 10 , CONR 10 R 11 , NR 10 COR 11 , NR 10 (CO)NR 11 R 12 , O(CO)NR 10 R 11 , NR 10 (CO)OR 11 , SO 2 R 10 , SOR 10 , SO 2 NR 10 R 11 , NR 10 SO 2 NR 11 R 12  and NR 10 SO 2 R 11 ; and  
   R b  denotes hydrogen.    
   
   
       5 . The compound according to  claim 4 , 
 wherein    A, R a  and R b  may have the meaning specified and    R 1  denotes hydrogen, C 1 -C 5 -alkyl or C 3 -C 8 -cycloalkyl,    R 2  denotes hydrogen, C 1 -C 5 -alkyl or C 3 -C 8 -cycloalkyl, phenyl 
 or  
   R 1  and R 2  together form an optionally substituted five- or six-membered ring consisting of carbon atoms and optionally 1 to 2 nitrogen atoms, 
 or  
   R 1  and R 2  together form an optionally substituted nine- to thirteen-membered spirocyclic ring, 
 or  
   R 1 , R 2  which may be identical or different, denote a group selected from among general formulae (A1)-A(17), 
 wherein  
   X denotes a bond or an optionally substituted C 1 -C 3 -alkylene, 
 or  
   X together with R 1 , R 3  or R 4  may form a 5- or 6-membered heterocyclic group;    Q denotes an optionally substituted C 1 -C 3 -alkylene,    Q together with R 1 , R 3  or R 4  may form a C 1 -C 7 -alkylene bridge;    R 3 , R 4 , R 5  which may be identical or different, denote hydrogen or an optionally substituted group selected from among C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 6 -cycloalkyl, C 3 -C 8 -heterocycloalkyl, —C 1 -C 3 -alkyl-C 3 -C 6 -cycloalkyl, phenyl and C 5 -C 10 -heteroaryl 
 or in each case two of the substituents  
   R 3 , R 4 , R 5  together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.    
   
   
       6 . The compound according to  claim 4 , 
 wherein    A, R a  and R b  may have the meaning specified and    R 1  denotes H, Me    R 2  denotes hydrogen or a group of general formulae (A18), 
 wherein  
   X denotes a bond or an optionally substituted group selected from among C 1 -C 7 -alkylene, C 3 -C 7 -alkenylene and C 3 -C 7 -alkynylene, 
 or  
   X together with R 1  may form a C 1-7  alkylene bridge    Y denotes a bond or methylene, ethylene;    X and Y may be linked to the same or different atoms of G, and    G denotes a saturated, partially saturated or unsaturated ring system consisting of 3-10 C atoms, wherein optionally up to 6 C atoms are replaced by heteroatoms selected from among nitrogen, oxygen and sulphur;    R 6  which may be identical or different, denote hydrogen or an optionally substituted group selected from among ═O, C 1 -C 4 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, C 6 -C 14 -aryl, C 5 -C 6 -heterocycloalkyl, and C 5 -C 6 -heteroaryl 
 or  
 a group selected from among NR 7 R 8 , OR 7 , —O—C 1 -C 3 -alkyl-NR 7 R 8 , CONR 7 R 8 , CO—C 1 -C 3 -alkyl-NR 7 R 8 , NR 7 COR 8 , NR 7 (CO)OR 8 , —CO—C 1 -C 3 -alkyl-NR 7 (CO)OR 8 , NR 7 (CO)NR 8 R 9 , NR 7 (CO)OR 8 , (CO)OR 7 , COR 7 , (SO 2 )R 7 , —C 1 -C 3 -alkyl-C 6 -C 14 -aryl, —NH—CO—NH—C 1 -C 3 -alkyl and CN  
   n denotes 1 or 2    R 7 , R 8 , R 9  which may be identical or different, denote hydrogen or an optionally substituted group selected from among C 1 -C 5 -alkyl, C 1 -C 4 -alkyl-C 6 -C 14 -aryl, C 3 -C 6 -heterocycloalkyl, C 1 -C 5 -alkyl-C 3 -C 8 -heterocycloalkyl- and C 3 -C 6 -cycloalkyl, 
 or in each case two of the substituents  
   R 7 , R 8 , R 9  together form an optionally substituted five- or six-membered ring, consisting of carbon atoms and optionally 1-2 heteroatoms, selected from among oxygen and nitrogen.    
   
   
       7 . A method of treating a disease or condition chosen from chronic bronchitis, acute bronchitis, bronchitis caused by bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary oedema, pneumonitis of different origins, e.g. radiation-induced or caused by aspiration, or infectious pneumonitis, collagenoses such as lupus erythematodes, systemic sclerodermy, sarcoidosis and Boeck's disease comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       8 . A method of treating a disease or condition chosen from psoriasis, contact dermatitis, atopic dermatitis, alopecia areata (circular hair loss), erythema exsudativum multiforme (Stevens-Johnson Syndrome), dermatitis herpetiformis, sclerodermy, vitiligo, nettle rash (urticaria), lupus erythematodes, follicular and surface pyodermy, endogenous and exogenous acne, acne rosacea and other inflammatory and allergic or proliferative skin diseases comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       9 . A method of treating a disease or condition chosen from inflammation of the conjunctiva (conjunctivitis) of various kinds, such as e.g. caused by infection with fungi or bacteria, allergic conjunctivitis, irritable conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       10 . A method of treating a disease or condition chosen from allergic rhinitis, allergic sinusitis and nasal polyps comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       11 . A method of treating a disease or condition chosen from Crohn's disease, ulcerative colitis, systemic lupus erythematodes, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, rheumatoid spondylitis comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       12 . A method of treating a disease or condition chosen from glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome comprising administering a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       13 . A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to  claim 1 .  
   
   
       14 . The pharmaceutical composition according to  claim 13  for inhalative administration.  
   
   
       15 . The pharmaceutical composition according to  claim 13  for oral administration.  
   
   
       16 . The pharmaceutical composition according to  claim 13 , comprising as a further active substance, one or more compounds which are selected from the categories of the betamimetics, anticholinergics, corticosteroids, other PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors or double or triple combinations thereof.